Location Directory

Clinical trials in Denver, Colorado

This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7451

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: COPD
Interventions: Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo; Biological · Other
Lead sponsor: Uniquity One (UNI); Industry
Eligibility: 40 Years to 75 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 94
States / cities: Birmingham, Alabama • Sheffield, Alabama • Peoria, Arizona + 82 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis
Interventions: Survodutide, Placebo matching survodutide; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 126
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions: Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo; Drug
Lead sponsor: Expedition Therapeutics, Inc; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 29
States / cities: Phoenix, Arizona • Encino, California • Northridge, California + 26 more

Conditions: Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma
Interventions: DBC-664; Biological
Lead sponsor: Duboce Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Denver, Colorado • Grand Rapids, Michigan • St Louis, Missouri + 4 more

Conditions: Cardiac Arrest, Out-Of-Hospital, Hypotension
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Denver, Colorado • Worcester, Massachusetts • Lebanon, New Hampshire + 5 more

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more

Conditions: Hernia, Ventral, Hernia, Hiatal, Hernia, Diaphragmatic, Incisional Hernia
Interventions: Gore ENFORM Biomaterial (Preperitoneal), Gore ENFORM Biomaterial (Intraperitoneal); Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: San Diego, California • Denver, Colorado • Sarasota, Florida + 6 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 390
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 46
States / cities: Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 42 more

Conditions: High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions: Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 1,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 181
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more

Clinical trials in Denver, Colorado

Filter and sort this location

Live official records

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

DBC-664 in Adult Patients With Solid Tumors

Cardiac Arrest - Ultrasound Detection of Occult Perfusion

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

GORE® ENFORM Biomaterial Product Study

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma